Iding Aaron F J, Ten Cate-Hoek Arina J
Thrombosis Expertise Center, Heart and Vascular Center, Maastricht University Medical Center, Maastricht, the Netherlands; Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands.
Thrombosis Expertise Center, Heart and Vascular Center, Maastricht University Medical Center, Maastricht, the Netherlands
Pol Arch Intern Med. 2022 Aug 22;132(7-8). doi: 10.20452/pamw.16288. Epub 2022 Jul 6.
Post‑thrombotic syndrome (PTS) is the most frequent complication of deep vein thrombosis, and it can be detrimental to the quality of life of the affected patients. Once affected by this chronic condition, the patient's treatment options are very limited, so preventive therapies are crucial. Currently, the prevention of PTS is hampered by the lack of unequivocally effective therapies. However, improved insight into pathogenesis of this condition acquired in recent years, including the central role of residual venous obstruction, could lead to a better application of existing therapies and identification of novel therapeutic targets. Plausible therapeutic agents include flavonoids and statins, while promising future agents include those that target leukocyte‑endothelial interaction. Moreover, differences in PTS risk were found to be partly explained by a tendency of patients to form clots that are less susceptible to lysis. Finally, identifying patients that are expected to benefit most from certain therapies is equally valuable for the success of future preventive strategies. This requires exploration of better risk stratification through machine learning techniques.
血栓形成后综合征（PTS）是深静脉血栓形成最常见的并发症，它会对受影响患者的生活质量产生不利影响。一旦患上这种慢性病，患者的治疗选择非常有限，因此预防性治疗至关重要。目前，由于缺乏明确有效的治疗方法，PTS的预防受到阻碍。然而，近年来对这种疾病发病机制的深入了解，包括残余静脉阻塞的核心作用，可能会导致现有治疗方法的更好应用以及新治疗靶点的识别。合理的治疗药物包括黄酮类化合物和他汀类药物，而未来有前景的药物包括那些针对白细胞 - 内皮细胞相互作用的药物。此外，发现PTS风险的差异部分可以通过患者形成不易溶解的血栓的倾向来解释。最后，识别出预计从某些治疗中获益最大的患者对于未来预防策略的成功同样具有重要价值。这需要通过机器学习技术探索更好的风险分层。
